Published • loading... • Updated
Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
The company said one Late-Breaking Abstract and four oral presentations will highlight ivonescimab, cadonilimab and other therapies across multiple tumor types.
- Akeso, Inc. announced yesterday that more than 40 clinical studies will be presented at the 2026 ASCO Annual Meeting in Chicago from May 29 to June 2, with HARMONi-6 overall survival data selected for the prestigious Plenary Session.
- The presentations underscore Akeso's differentiated bispecific antibody platform, featuring core first-in-class candidates cadonilimab and ivonescimab , alongside ligufalimab, a next-generation CD47 monoclonal antibody.
- Professor Shun Lu will present HARMONi-6 Phase III overall survival results as a Late-Breaking Abstract on May 31 at 2:47 PM CDT, comparing ivonescimab combined with chemotherapy versus a PD-1 inhibitor in first-line advanced squamous non-small cell lung cancer.
- Additional presentations span ivonescimab efficacy in small-cell lung cancer and first-line metastatic colorectal cancer, alongside cadonilimab-based regimens across multiple cancer types, with four Oral or Rapid Oral sessions complementing the Plenary selection.
- Founded in 2012, Akeso maintains a robust pipeline of over 50 innovative assets across cancer and other therapeutic areas, with 27 candidates in clinical trials including 15 bispecific/multispecific antibodies supported by proprietary platforms including Tetrabody technology and AI-powered drug discovery.
Insights by Ground AI
15 Articles
15 Articles
Waterloo Cedar Falls Courier+14 Reposted by 14 other sources
Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
HONG KONG, May 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking…
·Waterloo, United States
Read Full ArticleCoverage Details
Total News Sources15
Leaning Left1Leaning Right2Center10Last UpdatedBias Distribution77% Center
Bias Distribution
- 77% of the sources are Center
77% Center
C 77%
15%
Factuality
To view factuality data please Upgrade to Premium
